New Clinical End-points in Patients With Primary Sjögren's Syndrome
Status:
Not yet recruiting
Trial end date:
2025-04-05
Target enrollment:
Participant gender:
Summary
There are no approved treatments for pSS and the clinical endpoints currently used in
clinical trials are inadequate to capture all aspects of the disease that should be evaluated
in clinical trials. The newly developed composite endpoint: Sjögren's Tool for Assessing
Response to treatment (STAR) will allow a more specific and meaningful assessment of
treatment efficacy in pSS.
Because of the heterogeneity of the disease and of the central role of the interplay between
B- and T-cells in the pathogenesis, it is worth to evaluate combination of conventional
synthetic immunomodulatory drugs targeting both B- and T-cells.